News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Moves Secret Heart Drug to Phase III Trial


7/20/2012 7:36:45 AM

Roche Holding AG (ROG) is planning a final-stage trial of a drug that taps into a gene mutation to lower cholesterol and heart attack risk beyond what statins such as Pfizer Inc. (PFE) (PFE)’s $9.6 billion-selling Lipitor can do. The experimental treatment, developed by the drugmaker’s Genentech unit, has been tested in enough people to show it reduces bad cholesterol as expected, said Hal Barron, chief medical officer at Basel, Switzerland-based Roche. Roche hasn’t published data on the drug or mentioned it in news releases.

Read at BusinessWeek

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES